With our in-house technology platform, scientific expertise in the inner ear, and network of experts, Sensorion can continually develop and optimize its pipeline and market expertise. Consequently, we are poised to expand our pipeline and facilitate other pharmaceutical collaborations.

We select and develop drug candidates from a pool of compounds in late pre-clinical and clinical stage development obtained from partnerships, collaborations and publically available drug libraries.

Sensorion has two therapeutic solutions being evaluated in clinical trials:
SENS-111 and SENS-401

2018 02 pipeline

Latest news

  • 23 Apr 2018

    Sensorion and Uconn Health Announce Identification of First Potential Biomarker for Noise-Induced Hearing Loss. Read

  • 23 Apr 2018

    Sensorion’s SENS-401 Reduces Hearing Loss in Preclinical Study When Oral Administration Initiated Up to Four Days after Acoustic Trauma. Read

Patient center

Corporate presentation